SRR662725
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- COAGULATION+0.406
- KRAS_SIGNALING_DN+0.405
- TNFA_SIGNALING_VIA_NFKB+0.376
- MYOGENESIS+0.375
- INFLAMMATORY_RESPONSE+0.349
- APICAL_SURFACE+0.323
- PANCREAS_BETA_CELLS+0.289
- ANGIOGENESIS+0.267
- XENOBIOTIC_METABOLISM+0.258
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.230
Top 10 suppressed
- PROTEIN_SECRETION-0.496
- MITOTIC_SPINDLE-0.459
- G2M_CHECKPOINT-0.433
- MYC_TARGETS_V1-0.417
- NOTCH_SIGNALING-0.410
- E2F_TARGETS-0.383
- DNA_REPAIR-0.372
- WNT_BETA_CATENIN_SIGNALING-0.362
- INTERFERON_ALPHA_RESPONSE-0.333
- UNFOLDED_PROTEIN_RESPONSE-0.316
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR656564 | GTEX | — | 0.935 |
| 2 | SRR659780 | GTEX | — | 0.927 |
| 3 | SRR1085662 | GTEX | — | 0.916 |
| 4 | SRR1319019 | GTEX | — | 0.904 |
| 5 | SRR1476571 | GTEX | — | 0.888 |
| 6 | SRR660330 | GTEX | — | 0.879 |
| 7 | SRR1443895 | GTEX | — | 0.873 |
| 8 | SRR1079281 | GTEX | — | 0.871 |
| 9 | SRR1420215 | GTEX | — | 0.868 |
| 10 | SRR1418818 | GTEX | — | 0.867 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| COAGULATION | 0.406 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.405 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.376 | Inavolisib | — uncovered |
| MYOGENESIS | 0.375 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.349 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.323 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.289 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.267 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.258 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.230 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.223 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.201 | Idelalisib | — uncovered |
| HYPOXIA | 0.192 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.133 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.131 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.110 | Inavolisib | — uncovered |
| APOPTOSIS | 0.109 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.095 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.094 | Inavolisib | — uncovered |